ADCs represent a new era of targeted cancer therapy with 15 approved drugs. However, over 100 discontinued ADC programs and similar number of active clinical trials highlight the difficulties of identifying the optimal combination of antibody, target, payload, linker, drug-antibody-ratio and indication.